Alnylam Pharmaceuticals market cap ALNY

Share price times shares outstanding: what the whole company sells for, since 2010.

Alnylam Pharmaceuticals is worth $30B at the close on Oct 23, 2026, at $224.03 a share.

That is down 51% over the last year and up 57% over five years.

Its highest close in our data was $63.1B in Oct 2025.

Market cap over time

Year	End of year	Low	High	Change
2026 so far	$30B	$27.5B	$52.9B	−43%
2025	$52.9B	$30.2B	$63.1B	+72%
2024	$30.7B	$18B	$38B	+28%
2023	$24B	$19B	$29B	−18%
2022	$29.2B	$15.3B	$29.3B	+44%
2021	$20.3B	$15.4B	$24.8B	+34%
2020	$15.1B	$11.4B	$18.6B	+15%
2019	$13.1B	$7.2B	$13.8B	+84%
2018	$7.1B	$6.4B	$14.5B	−40%
2017	$11.8B	$3.3B	$13B	+267%
2016	$3.2B	$2.9B	$7.2B	−60%
2015	$8B	$6.7B	$11.5B	+6%
2014	$7.5B	$3.2B	$7.7B	+82%
2013	$4.1B	$998M	$4.2B	+347%
2012	$925.6M	$370.4M	$1.1B	+166%
2011	$348.2M	$272.1M	$481M	−16%
2010	$416.1M	$389.9M	$627.7M	n/a

Companies in Biotechnology nearest Alnylam Pharmaceuticals' size, closest first, today.

Company	Market cap
ALNYAlnylam Pharmaceuticals	$30B
UTHRUnited Therapeutics	$25.2B
INCYIncyte	$23.5B
ONCBeOne Medicines	$42.9B
EXELExelixis	$16B
NBIXNeurocrine Biosciences	$14.5B
HALOHalozyme Therapeutics	$14.3B
TECHBIO-TECHNE	$11.4B
REGNRegeneron Pharmaceuticals	$82.9B
RGENRepligen	$10B
KRYSKrystal Biotech	$9.2B
Peer median	$15.2B